Dashboard
Manage Tickers

APLSApellis Pharmaceuticals, Inc.

Nasdaq apellis.com


$ 39.62 $ 0.37 (0.94 %)    

Wednesday, 31-Jul-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 473.02 $ 13.54 (2.96 %)
DIA $ 408.46 $ 1.08 (0.27 %)
SPY $ 551.56 $ 8.81 (1.63 %)
TLT $ 94.83 $ 0.96 (1.02 %)
GLD $ 226.56 $ 4.03 (1.81 %)
$ 39.6
$ 39.60 x 100
-- x --
-- - --
$ 19.83 - $ 73.80
1,919,740
na
4.87B
$ 0.90
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 02-27-2024 12-31-2023 10-K
3 11-01-2023 09-30-2023 10-Q
4 07-31-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-21-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-28-2022 12-31-2021 10-K
11 11-08-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 04-28-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-02-2020 09-30-2020 10-Q
16 07-30-2020 06-30-2020 10-Q
17 04-29-2020 03-31-2020 10-Q
18 02-27-2020 12-31-2019 10-K
19 11-05-2019 09-30-2019 10-Q
20 07-31-2019 06-30-2019 10-Q
21 05-07-2019 03-31-2019 10-Q
22 02-26-2019 12-31-2018 10-K
23 11-13-2018 09-30-2018 10-Q
24 07-31-2018 06-30-2018 10-Q
25 04-30-2018 03-31-2018 10-Q
26 03-19-2018 12-31-2017 10-K
27 12-20-2017 09-30-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

jefferies-maintains-buy-on-apellis-pharmaceuticals-maintains-80-price-target
Jefferies Maintains Buy on Apellis Pharmac...
07/31/2024 18:04:23

Jefferies analyst Akash Tewari maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $80 price target.

watching-apellis-pharmaceuticals-traders-circulate-comments-from-jefferies-suggesting-the-fda-has-put-out-a-faers-update-which-included-a-new-additional-death-on-syfovre-says-does-not-change-our-view-on-syfovres-safety
Watching Apellis Pharmaceuticals; Traders ...
07/31/2024 14:55:34

https://fis.fda.gov/sense/app/95239e26-e0be-42d9-a960-9a5f7f1c25ee/sheet/45beeb74-30ab-46be-8267-5756582633b4/state/analysis

baird-maintains-outperform-on-apellis-pharmaceuticals-lowers-price-target-to-86
Baird Maintains Outperform on Apellis Phar...
07/26/2024 11:15:29

Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and lowers the price target fro...

baird-maintains-outperform-on-apellis-pharmaceuticals-maintains-100-price-target
Baird Maintains Outperform on Apellis Phar...
07/23/2024 20:42:14

Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and maintains $100 price target.

peeling-back-the-layers-exploring-apellis-pharmaceuticals-through-analyst-insights
Peeling Back The Layers: Exploring Apellis...
07/17/2024 17:01:42

goldman-sachs-maintains-buy-on-apellis-pharmaceuticals-lowers-price-target-to-77
Goldman Sachs Maintains Buy on Apellis Pha...
07/17/2024 15:57:10

Goldman Sachs analyst Salveen Richter maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target...

what-analysts-are-saying-about-apellis-pharmaceuticals-stock
What Analysts Are Saying About Apellis Pha...
06/28/2024 20:02:39

baird-maintains-outperform-on-apellis-pharmaceuticals-maintains-100-price-target
Baird Maintains Outperform on Apellis Phar...
06/28/2024 17:10:19

Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and maintains $100 price target.

nike-accolade-and-other-big-stocks-moving-lower-in-fridays-pre-market-session
Nike, Accolade And Other Big Stocks Moving...
06/28/2024 13:08:43

apellis-committee-says-it-plans-to-seek-re-examination-following-negative-chmp-opinion-for-pegcetacoplan-for-geographic-atrophy-in-the-eu
Apellis Committee Says It Plans To Seek Re...
06/28/2024 11:01:10

piper-sandler-initiates-coverage-on-apellis-pharmaceuticals-with-neutral-rating-announces-price-target-of-46
Piper Sandler Initiates Coverage On Apelli...
05/31/2024 09:55:14

Piper Sandler analyst Biren Amin initiates coverage on Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral rating and annou...

expert-outlook-apellis-pharmaceuticals-through-the-eyes-of-15-analysts
Expert Outlook: Apellis Pharmaceuticals Th...
05/28/2024 14:00:27

hc-wainwright--co-reiterates-buy-on-apellis-pharmaceuticals-maintains-92-price-target
HC Wainwright & Co. Reiterates Buy on Apel...
05/28/2024 10:31:22

HC Wainwright & Co. analyst Douglas Tsao reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $92 p...

apellis-pharmaceuticals-and-sobi-announce-positive-one-year-results-from-phase-2-noble-study-of-pegcetacoplan-for-post-transplant-recurrence-of-c3-glomerulopathy-c3g-and-ic-mpgn
Apellis Pharmaceuticals And Sobi Announce ...
05/24/2024 14:01:58

Rapid reduction in disease activity seen at 12 weeks was sustained at one year55% of patients showed zero C3c staining intensit...

wells-fargo-maintains-equal-weight-on-apellis-pharmaceuticals-lowers-price-target-to-48
Wells Fargo Maintains Equal-Weight on Apel...
05/23/2024 14:27:27

Wells Fargo analyst Derek Archila maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Equal-Weight and lowers the price t...

apellis-pharmaceuticals-refinances-existing-debt-with-up-to-475m-non-dilutive-credit-facility
Apellis Pharmaceuticals Refinances Existin...
05/14/2024 12:30:09

Apellis received $375 million in funding at close, with ability to access an additional $100 millionMajority of initial proceed...

citigroup-maintains-buy-on-apellis-pharmaceuticals-lowers-price-target-to-60
Citigroup Maintains Buy on Apellis Pharmac...
05/08/2024 19:34:29

Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target f...

hc-wainwright--co-reiterates-buy-on-apellis-pharmaceuticals-maintains-92-price-target
HC Wainwright & Co. Reiterates Buy on Apel...
05/08/2024 19:08:49

HC Wainwright & Co. analyst Douglas Tsao reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $92 p...

in-depth-examination-of-14-analyst-recommendations-for-apellis-pharmaceuticals
In-Depth Examination Of 14 Analyst Recomme...
05/08/2024 18:00:15

ubs-maintains-buy-on-apellis-pharmaceuticals-lowers-price-target-to-85
UBS Maintains Buy on Apellis Pharmaceutica...
05/08/2024 13:14:20

UBS analyst Eliana Merle maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $89 to ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

08/02/2024 Humana Inc. (HUM)
08/05/2024 Marinus Pharmaceuticals, Inc. (MRNS)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)